Table 3 Doses escalation during the study follow up

Mirtazapine: 15 mg

Escitalopram: 10 mg (or 5 mg for patients older than 65)

Excessive drowsiness

(CTCAE grade 1 or rated moderate or severe using the ASEC)

For patients under 65 in the escitalopram arm: decrease to 5 mg

For every other patients: Stop the treatment

Any severe adverse effect or serious adverse event

(CTCAE grade > 3 or rated severe using the l’ASEC)

Stop the treatment

Moderate adverse event

(CTCAE grade 2 or rated moderate using the ASEC)

Decrease the dosage

(Or treatment stop if already at the lower dosage)

Mild adverse event

(CTCAE grade 1 or rated mild using the ASEC)

No dose adjustment

No adverse event

Inadequate symptoms’ control (ESAS > 3)

No dose adjustment

(or increase the dosage if escitalopram has been started at 5 mg)

Increase the dosage

Adequate symptoms’ control

(ESAS ≤ 3)

No dose adjustment